8-K: Xeris Biopharma Reports Strong Q1 2026 Results, Raises Guidance

Xeris Biopharma announced a 43% year-over-year increase in total product revenue for Q1 2026, reaching over $82 million, and tightened its full-year revenue guidance.

Summary

• Xeris Biopharma reported first quarter 2026 financial results with total revenue of $83.1 million, a 38% increase year-over-year.
• Product revenue grew by 43% to $82.5 million, driven by a 95% increase in Recorlev net revenue to $49.8 million.
• Gvoke net revenue was $20.8 million, flat year-over-year, and Keveyis net revenue increased 4% to $11.9 million.
• Gross margin improved to 87% from 85% in the prior year's quarter.
• Net income for the quarter was $2.2 million, a significant improvement from a net loss of $9.2 million in Q1 2025.
• Adjusted EBITDA was $15.1 million, up from $4.4 million in the same period last year.
• The company tightened its full-year 2026 total revenue guidance to $380 million to $390 million, representing over 30% growth at the midpoint.
• Phase 3 initiation of XP-8121 is anticipated later in 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, improved profitability, and raised guidance, indicating robust operational performance and positive future prospects.

Positives

• Total product revenue increased 43% year-over-year to over $82 million.
• Recorlev net revenue nearly doubled, increasing 95% year-over-year to $49.8 million.
• Gross margin improved to 87% from 85% in Q1 2025.
• Achieved net income of $2.2 million, a substantial turnaround from a net loss of $9.2 million in Q1 2025.
• Adjusted EBITDA significantly improved to $15.1 million from $4.4 million in Q1 2025.
• Tightened full-year 2026 total revenue guidance to $380 million - $390 million, indicating confidence in continued growth.
• Successful expansion of the commercial team completed, with expected impact in the second half of 2026.
• XP-8121 Phase 3 initiation is on track for later in 2026, a key pipeline development.

Negatives

• Gvoke net revenue was flat year-over-year at $20.8 million.
• Royalty, contract and other revenue decreased by 71% to $0.7 million from $2.3 million in Q1 2025.
• R&D expenses increased 13% to $8.8 million, primarily due to support for XP-8121.
• SG&A expenses increased 21% to $53.1 million, mainly for commercial enterprise support and Recorlev expansion.

Risks

• Reliance on third-party suppliers, including single-source suppliers.
• Reliance on third parties to conduct clinical trials.
• Ability of product candidates to compete successfully with existing and new drugs.
• Ability to protect intellectual property and proprietary technology.
• Accuracy and completeness of assumptions and ability to accurately estimate future financial results and market opportunities.
• General macroeconomic and geopolitical conditions, including economic downturns, political unrest, trade disputes, changes in U.S. governmental priorities and resources, tariffs, export controls, and market volatility.
• Potential need for financing to fund product development programs or commercialization efforts.
• Uncertainty regarding market acceptance of products in a competitive environment.

Future Outlook

The company has tightened its full-year 2026 total revenue guidance to $380 million to $390 million, representing more than 30% growth at the midpoint. Management is confident in their ability to deliver on financial targets and expects the impact of commercial team expansion to become more evident in the second half of 2026. The Phase 3 initiation of XP-8121 is anticipated later in 2026.

Management Comments

• "We are thrilled with our outstanding start to 2026, delivering first quarter net product revenue growth of 43%, reflecting the successful execution of our strategy."
• "Recorlev was the standout performer, with net revenue nearly doubling year-over-year, driven by growth across our patient base and increased awareness across the prescriber base."
• "Looking ahead, we remain confident in our ability to deliver on our full-year financial targets. Recorlev's strong Q1 and continued momentum gives us the confidence to raise the bottom end of our full year 2026 total revenue guidance."
• "Our updated guidance of $380 million to $390 million represents more than 30% growth at the midpoint."
• "Beyond our commercial execution, 2026 represents a pivotal year for our pipeline, with the anticipated Phase 3 initiation of XP-8121 later in the year marking a significant value creation inflection point."

Industry Context

StockSavvy.ai notes that Xeris Biopharma's strong Q1 2026 performance, particularly the significant growth in Recorlev revenue, aligns with a trend of increasing demand for specialized biopharmaceutical products. The company's focus on pipeline development, specifically the upcoming Phase 3 trial for XP-8121, reflects a strategic approach to long-term value creation common among growth-oriented biopharma companies.

Comparison to Industry Standards

• The 43% year-over-year product revenue growth is significantly above the average growth rates seen in many mature pharmaceutical segments, indicating strong market penetration and demand for Xeris's products.
• The improvement in gross margin to 87% suggests efficient manufacturing and favorable product mix, which is a positive indicator compared to industry averages that can be impacted by higher cost of goods sold.
• The turnaround from a net loss to net income, coupled with a substantial increase in Adjusted EBITDA, demonstrates effective operational management and a path towards profitability, a key benchmark for investors in the biopharmaceutical sector.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong financial performance, improved profitability, and raised full-year guidance. Continued pipeline development (XP-8121) offers future growth potential.
• Employees: Expansion of the commercial team indicates investment in growth and potential for increased opportunities. Increased R&D spending suggests continued focus on pipeline advancement.
• Customers: Continued availability and growth of products like Recorlev, Gvoke, and Keveyis are critical for patient treatment.
• Suppliers: Increased product revenue may lead to higher demand for raw materials and manufacturing services.

Next Steps

• Participate in 1x1 meetings at the Craig-Hallum Institutional Investor Conference on May 28, 2026.
• Participate in 1x1 meetings and a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026.
• Anticipate Phase 3 initiation of XP-8121 later in 2026.
• Expect the impact of commercial team investments to become more evident in the second half of 2026 and beyond.

Key Dates

Recommendation

The company has demonstrated exceptional revenue growth, a significant turnaround in profitability, and raised its full-year guidance, driven by strong performance in key products like Recorlev. The pipeline advancement with XP-8121 further supports a positive outlook. These factors collectively suggest a compelling investment opportunity with significant upside potential.

Keywords

Xeris Biopharma, 8-K Filing, Q1 2026 Earnings, Recorlev, Gvoke, Keveyis, XP-8121, Biopharmaceutical